The American Journal of Managed Care2d
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Healio1d
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Monthly Prescribing Reference2d
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
WAMC2d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The Grand Junction Daily Sentinel1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Hosted on MSN2d
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...
Philippine Daily Inquirer3d
Ketamine a lifeline for severe depression patients in Singapore
Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray ... to give numbers for Singapore, but Spravato is available at about 2,800 ...
The Straits Times3d
Controlled drug Ketamine a lifeline for patients with severe depression in S’pore
Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray ... the ketamine nasal spray Spravato is now a mainstream prescription for ...
pharmaphorum5d
J&J builds case for antidepressant Spravato with head-to-head trial
Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...
tnp.straitstimes3d
Ketamine a lifeline for patients with severe depression
Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious ... Once seen as an alternative option, the ketamine nasal spray Spravato ...